These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 21309667)
1. XELOX in colorectal cancer: a convenient option for the future? Lindsay CR; Cassidy J Expert Rev Gastroenterol Hepatol; 2011 Feb; 5(1):9-19. PubMed ID: 21309667 [TBL] [Abstract][Full Text] [Related]
2. Cost-minimisation analysis in first-line treatment of metastatic colorectal cancer in France: XELOX versus FOLFOX-6. Perrocheau G; Bennouna J; Ducreux M; Hebbar M; Ychou M; Lledo G; Conroy T; Dominguez S; Faroux R; Florentin V; Douillard JY Oncology; 2010; 79(3-4):174-80. PubMed ID: 21358204 [TBL] [Abstract][Full Text] [Related]
3. Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: implications for health-care utilization in Australia. Tran G; Hack SP; Kerr A; Stokes L; Gibbs P; Price T; Todd C Asia Pac J Clin Oncol; 2013 Sep; 9(3):239-48. PubMed ID: 23279720 [TBL] [Abstract][Full Text] [Related]
4. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin. Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749 [TBL] [Abstract][Full Text] [Related]
5. Xelox (capecitabine plus oxaliplatin) as neoadjuvant chemotherapy of unresectable liver metastases in colorectal cancer patients. Coskun U; Buyukberber S; Yaman E; Uner A; Er O; Ozkan M; Dikilitas M; Oguz M; Yildiz R; B DY; Kaya AO; Benekli M Neoplasma; 2008; 55(1):65-70. PubMed ID: 18190244 [TBL] [Abstract][Full Text] [Related]
8. Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands. Jansman FG; Postma MJ; van Hartskamp D; Willemse PH; Brouwers JR Clin Ther; 2004 Apr; 26(4):579-89. PubMed ID: 15189755 [TBL] [Abstract][Full Text] [Related]
9. Oxaliplatin for the treatment of advanced colorectal cancer: future directions. Ducreux M; Louvet C; Bekradda M; Cvitkovic E Semin Oncol; 1998 Apr; 25(2 Suppl 5):47-53. PubMed ID: 9609108 [TBL] [Abstract][Full Text] [Related]
10. Capecitabine, alone and in combination, in the management of patients with colorectal cancer: a review of the evidence. Comella P; Casaretti R; Sandomenico C; Avallone A; Franco L Drugs; 2008; 68(7):949-61. PubMed ID: 18457461 [TBL] [Abstract][Full Text] [Related]
11. [Cost analysis of XELOX and FOLFOX-4 chemotherapy regimens for colorectal carcinoma]. Büchler T; Nohejlová Medková A; Kupec M; Bláha M; Pavlík T; Dušek L; Abrahámová J Klin Onkol; 2012; 25(6):440-4. PubMed ID: 23301646 [TBL] [Abstract][Full Text] [Related]
12. [Tolerability of XELOX in postoperative adjuvant chemotherapy for colorectal cancer]. Matsuda C; Danno K; Miyazaki S; Fujitani K; Kubota M; Kawada J; Takagi M; Fukui A; Iwase K; Tanaka Y Gan To Kagaku Ryoho; 2014 Jun; 41(6):743-7. PubMed ID: 25129086 [TBL] [Abstract][Full Text] [Related]
13. The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer. Almond J; Ralston S Br J Cancer; 2007 May; 96(9):1489; author reply 1490. PubMed ID: 17437019 [No Abstract] [Full Text] [Related]
14. Cost identification of Nordic FLIRI, Nordic FLOX, XELIRI and XELOX in first-line treatment of advanced colorectal cancer in Sweden -- a clinical practice model approach. Pettersson K; Carlsson G; Holmberg C; Sporrong SK Acta Oncol; 2012 Sep; 51(7):840-8. PubMed ID: 22937953 [TBL] [Abstract][Full Text] [Related]
15. Health economic analysis of fluoropyrimidine-based therapies of colorectal cancer from the perspective of statutory sickness funds. Grothey A; Kleeberg UR; Stauch M; Hieke K Z Gastroenterol; 2005 Feb; 43(2):155-61. PubMed ID: 15700205 [TBL] [Abstract][Full Text] [Related]
16. Capecitabine and docetaxel combination for the treatment of breast cancer. Morishita M; Leonard RC Womens Health (Lond); 2008 Jan; 4():11-22. PubMed ID: 19072447 [TBL] [Abstract][Full Text] [Related]
17. Cost consequences of adjuvant capecitabine, Mayo Clinic and de Gramont regimens for stage III colon cancer in the French setting. Douillard JY; Tilleul P; Ychou M; Dufour P; Perrocheau G; Seitz JF; Maes P; Lafuma A; Husseini F Oncology; 2007; 72(3-4):248-54. PubMed ID: 18185019 [TBL] [Abstract][Full Text] [Related]
18. Cost analysis of adjuvant therapy with XELOX or FOLFOX4 for colon cancer. Xie Q; Wen F; Wei YQ; Deng HX; Li Q Colorectal Dis; 2013 Aug; 15(8):958-62. PubMed ID: 23506229 [TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school. Ungari AQ; Pereira LRL; Nunes AA; Peria FM BMC Cancer; 2017 Oct; 17(1):691. PubMed ID: 29041915 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]